Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma.
Melanoma Manag
; 2(1): 41-50, 2015 Feb.
Article
in En
| MEDLINE
| ID: mdl-30190830
ABSTRACT
Programmed cell death receptor-1 (PD-1) and programmed cell death-1 ligand-1 (PD-L1) represent promising novel targets in immunotherapy. PD-1 is an inhibitory receptor involved in T-cell regulation that is expressed by activated T cells. Nivolumab and pembrolizumab are anti-PD-1 antibodies that have shown antitumor activity and acceptable tolerability in patients with metastatic melanoma in preclinical development and Phase I/II clinical trials. Several ongoing Phase III studies are further investigating the efficacy and safety of anti-PD-1 therapy in melanoma. Initial data on the combination of anti-PD-1 and anti-cytotoxic T-lymphocyte-associated antigen 4 blockade with nivolumab and ipilimumab also appear promising. Monoclonal antibodies to blockade PD-L1 may also be an effective immunotherapy strategy in melanoma and several anti-PD-L1 antibodies are in development.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Melanoma Manag
Year:
2015
Document type:
Article
Affiliation country:
Italy